Several other analysts have also issued reports on the company. Oppenheimer reduced their target price on Compugen from $14.00 to $12.00 and set an outperform rating on the stock in a report on Monday, August 8th. Truist Financial reduced their price objective on Compugen from $14.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, August 23rd. JMP Securities reduced their price objective on Compugen from $8.00 to $4.00 and set a market outperform rating on the stock in a research note on Monday, August 8th. Finally, Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 price objective on the stock. in a research note on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $6.20.
Compugen Price Performance
Shares of NASDAQ CGEN opened at $0.80 on Tuesday. The stock’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $2.01. Compugen has a one year low of $0.79 and a one year high of $7.48. The firm has a market cap of $69.23 million, a price-to-earnings ratio of -2.05 and a beta of 2.15.
Hedge Funds Weigh In On Compugen
Hedge funds have recently made changes to their positions in the stock. Taylor Frigon Capital Management LLC raised its position in shares of Compugen by 1.9% during the first quarter. Taylor Frigon Capital Management LLC now owns 672,055 shares of the biotechnology company’s stock worth $2,164,000 after acquiring an additional 12,769 shares during the last quarter. Eagle Rock Investment Company LLC bought a new position in shares of Compugen during the fourth quarter worth about $83,000. Qube Research & Technologies Ltd bought a new position in shares of Compugen during the first quarter worth about $85,000. WMS Partners LLC bought a new position in shares of Compugen during the first quarter worth about $74,000. Finally, Antonetti Capital Management LLC increased its holdings in Compugen by 41.5% in the first quarter. Antonetti Capital Management LLC now owns 350,671 shares of the biotechnology company’s stock worth $1,129,000 after purchasing an additional 102,771 shares in the last quarter.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.